Corbus Pharmaceuticals Doses First Patient in Registrational CRB-701 Throat Cancer Trial

Key Points 

• TEMPO-1 is a randomized study expected to enroll 250 patients with second-line or later OPSCC.
• The trial will compare CRB-701 with the investigator’s choice of capecitabine, cetuximab or docetaxel.
• Its primary endpoint is objective response rate, intended to support a potential accelerated approval; overall survival is intended to support a potential conversion to full approval.
• In an earlier analysis of patients receiving a 3.6 mg/kg dose, Corbus reported a confirmed objective response rate of 42.9%.
• Corbus estimates that approximately 14,000 U.S. OPSCC patients become eligible for second-line treatment annually.

Corbus Pharmaceuticals (NASDAQ: CRBP) has dosed the first patient in TEMPO-1, a registrational study of its Nectin-4-targeted antibody-drug conjugate CRB-701 in second-line or later oropharyngeal squamous cell carcinoma (OPSCC). The trial is designed to compare CRB-701 with existing treatment options and could provide evidence for a potential FDA submission.

TEMPO-1 Trial Tests CRB-701 Against Existing Treatments

TEMPO-1 will assess both the efficacy and safety of CRB-701 in patients whose OPSCC requires second-line or later treatment. Randomization and an active comparator group should allow Corbus to evaluate the drug against the treatment choices specified in the study, rather than relying only on results from an earlier-stage trial.

The study’s primary measure is objective response rate, the proportion of patients whose tumors shrink by a defined amount. Corbus intends that endpoint to support a potential accelerated approval application. Overall survival is intended to support a possible later conversion to full approval. Neither outcome, nor FDA approval of CRB-701, is assured.

Earlier CRB-701 Data Support Further Testing

Corbus said results from its ongoing Phase 1/2 study, presented at the 2026 American Society of Clinical Oncology annual meeting, supported proceeding with TEMPO-1. Among second-line or later OPSCC patients treated at 3.6 mg/kg, the company reported a confirmed objective response rate of 42.9%, a median response duration of 6.3 months and median progression-free survival of 5.6 months; the progression-free survival analysis was ongoing.

Those results provide a rationale for the registrational trial, but they do not establish how CRB-701 will perform against the TEMPO-1 comparison treatments. The announcement does not state how many patients were included in that earlier OPSCC analysis.

OPSCC Patient Population Shapes the Opportunity

OPSCC is a cancer of the oropharynx, part of the throat. Corbus says its incidence and prevalence in the United States are rising, largely driven by HPV infection. The company estimates that OPSCC accounts for roughly half of U.S. head and neck cancer patients in the second-line or later setting, with approximately 14,000 OPSCC patients eligible for second-line treatment each year.

These figures describe the potential treatment population, not a sales forecast. CRB-701 remains an investigational therapy, and the announcement does not provide a timeline for TEMPO-1 results or a regulatory submission.

Investor Takeaway: Trial Execution Is the Next Test

For CRBP investors, first-patient dosing marks the transition from planning TEMPO-1 to conducting it. The central question is whether the response signal reported in the earlier study holds up in a randomized trial while maintaining an acceptable safety profile.

CRB-701 has received FDA Fast Track designations in head and neck squamous cell carcinoma and cervical cancer. Those designations do not mean the drug is approved; enrollment, comparative results and any subsequent regulatory review remain ahead.